Marfan syndrome (MFS) is a genetic disorder caused by mutations in the FBN1 gene, which encodes fibrillin-1, a crucial protein involved in the structure of elastic fibers and the regulation of transforming growth factor-beta (TGF-β) bioavailability. Defective fibrillin-1 disrupts these fibers, leading to skeletal, ocular, and cardiovascular abnormalities. A key pathological mechanism in MFS is excessive TGF-β signaling, which has been targeted by angiotensin receptor blocker (ARB) therapies such as losartan, demonstrating potential in restoring normal phenotypes in experimental models. The aim of this narrative review was to highlight findings that demonstrate the potential of ARBs for MFS. Aortic root dilation is a defining feature of MFS. Studies have shown that losartan therapy significantly reduces the dimensions of the aortic root and sinotubular junction in children. However, its long-term efficacy remains uncertain. Beyond its primary effects on the aorta, chronic losartan treatment enhances endothelial function by promoting nitric oxide-mediated vasodilation, which may help prevent aortic root widening. The drug’s effects are partly attributed to its metabolites, EXP3174 (an angiotensin II type 1 receptor [AT1] antagonist) and EXP3179 (an NADPH oxidase inhibitor). Overexpression of NADPH oxidase in MFS contributes to vascular dysfunction, and EXP3179 mitigates aortic vasoconstriction. Given these mechanisms, ongoing research explores the potential of AT1 receptor antagonists as therapeutic agents in MFS, aiming to improve vascular health and long-term patient outcomes.
DietzH. FBN1-related Marfan syndrome. In: AdamMPFeldmanJMirzaaGMet al. (eds) GeneReviews® [Internet]. University of Washington, Seattle, 1993–2025.
6.
SengleGSakaiLY.The fibrillin microfibril scaffold: A niche for growth factors and mechanosensation?Matrix Biol2015; 47: 3–12.
7.
LiLHuangJLiuY.The extracellular matrix glycoprotein fibrillin-1 in health and disease. Front Cell Dev Biol2024; 11: 1302285.
8.
NeptuneERFrischmeyerPAArkingDE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet2003; 33: 407–411.
9.
HabashiJPJudgeDPHolmTM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science2006; 312: 117–121.
10.
LimDSLutucutaSBachireddyP, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation2001; 103: 789–791.
11.
HallbergPLindLBillbergerK, et al. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment—Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol2004; 27: 169–173.
12.
TehraniAYWhiteZTungLW, et al. Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects. Sci Rep2022; 12: 9771.
13.
TehraniAYZhaoRDonenGBernatchezP.Heterogenous improvements in endothelial function by sub-blood pressure lowering doses of ARBs result in major anti-aortic root remodeling effects. Nitric Oxide2023; 131: 18–25.
14.
MarfanBJA. [A case of congenital deformity of the four limbs, more pronounced at the extremities, characterized by lengthening of the bones with a certain degree of thinning] [Article in French]. Bull Mem Med Society Hospitals Paris. 1896; 13: 220–226.
15.
DietzHCPyeritzREHallBD, et al. The Marfan syndrome locus: Confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. Genomics1991; 9: 355–361.
16.
von KodolitschYDemolderAGirdauskasE, et al. Features of Marfan syndrome not listed in the Ghent nosology – The dark side of the disease. Expert Rev Cardiovasc Ther2019; 17: 883–915.
17.
ZeiglerSMSloanBJonesJA.Pathophysiology and pathogenesis of Marfan syndrome. Adv Exp Med Biol2021; 1348: 185–206.
18.
SakaiLYKeeneDREngvallE.Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol1986; 103(6 Pt 1): 2499–2509.
BaldwinAKSimpsonASteerR, et al. Elastic fibres in health and disease. Expert Rev Mol Med2013; 15: e8.
21.
SummersKM.Genetic models of fibrillinopathies. Genetics2024; 226: iyad189.
22.
de SouzaRBCassianoLLBarnowskiP, et al. Exploring thoracic aorta ECM alterations in Marfan syndrome: Insights into aorta wall structure. Sci Rep2025; 15: 26665.
23.
AstaLD’AngeloGAMarinelliDBenedettoU.Genetic basis, new diagnostic approaches, and updated therapeutic strategies of the syndromic aortic diseases: Marfan, Loeys-Dietz, and Vascular Ehlers-Danlos syndrome. Int J Environ Res Public Health2023; 20: 6615.
24.
IsogaiZOnoRNUshiroS, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem2003; 278: 2750–2757.
25.
HiraniRHanssenEGibsonMA.LTBP-2 specifically interacts with the amino-terminal region of fibrillin-1 and competes with LTBP-1 for binding to this microfibrillar protein. Matrix Biol2007; 26: 213–223.
26.
HabashiJPDoyleJJHolmTM, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science2011; 332: 361–365.
27.
HolmTMHabashiJPDoyleJJ, et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science2011; 332: 358–361.
28.
FukamiKUedaSYamagishiS, et al. AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int2004; 66: 2137–2147.
29.
LavoiePRobitailleGAgharaziiM, et al. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens2005; 23: 1895–1903.
30.
GambarinFIFavalliVSerioA, et al. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med (Hagerstown)2009; 10: 354–362.
31.
RadonicTde WittePBaarsMJ, et al. Losartan therapy in adults with Marfan syndrome: Study protocol of the multi-center randomized controlled COMPARE trial. Trials2010; 11: 3.
32.
DetaintDAegerterPTubachF, et al. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis2010; 103: 317–325.
33.
FortezaAEvangelistaASánchezV, et al. [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. [Article in Spanish]. Rev Esp Cardiol2011; 64: 492–498.
34.
MöbergKDe NobeleSDevosD, et al. The Ghent Marfan Trial—A randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers. Int J Cardiol2012; 157: 354–358.
35.
LacroRVGueyLTDietzHC, et al. Characteristics of children and young adults with Marfan syndrome and aortic root dilatation in a randomized trial comparing atenolol and losartan therapy. Am Heart J2013; 165: 828–835.
WeinrichJMLenzASchönG, et al. Magnetic resonance angiography derived predictors of progressive dilatation and surgery of the aortic root in Marfan syndrome. PLoS One2022; 17: e0262826.
38.
CoselliJSBarronLM.Lifetime aortic management in Marfan syndrome: Puzzle pieces and rare diseases. J Am Coll Cardiol2023; 82: 1077–1079.
39.
SaeyeldinAZafarMAVelasquezCA, et al. Natural history of aortic root aneurysms in Marfan syndrome. Ann Cardiothorac Surg2017; 6: 625–632.
40.
CarboneRGMonseliseAPuppoF.Marfan syndrome and aortic involvement: A narrative review. Eur Rev Med Pharmacol Sci2023; 27: 8218–8224.
41.
SandorGGAlghamdiMHRaffinLA, et al. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes. Int J Cardiol2015; 179: 470–475.
42.
IsselbacherEMPreventzaOHamilton BlackJ3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation2022; 146: e334–e482.
43.
BrookeBSHabashiJPJudgeDP, et al. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med2008; 358: 2787–2795.
44.
PeesCLacconeFHaglM, et al. Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol2013; 112: 1477–1483.
45.
MuellerGCStierleLStarkV, et al. Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome. Heart2014; 100: 214–218.
46.
HoskoppalAMenonSTrachtenbergF, et al. Predictors of rapid aortic root dilation and referral for aortic surgery in Marfan syndrome. Pediatr Cardiol2018; 39: 1453–1461.
47.
Selamet TierneyESLevineJCSleeperLA, et al. Influence of aortic stiffness on aortic-root growth rate and outcome in patients with the Marfan syndrome. Am J Cardiol2018; 121: 1094–1101.
48.
Van DriestSLSleeperLAGelbBD, et al. Variants in ADRB1 and CYP2C9: Association with response to atenolol and losartan in Marfan syndrome. J Pediatr2020; 222: 213–220.e5.
49.
PeesCHenoJMichel-BehnkeI.Initial angiotensin receptor blocker response in young Marfan patients decreases after 3 years of treatment. Pediatr Cardiol2022; 43: 586–595.
50.
Di ToroAKlersyCGiulianiL, et al. Losartan vs nebivolol vs the association of both on the progression of aortic root dilation in genotyped Marfan syndrome: 48 months open label randomized controlled phase III trial. Eur Heart J2019; 40: ehz746.0154.
51.
PitcherASpataEEmbersonJ, et alMarfan Treatment Trialists’ Collaboration. Angiotensin receptor blockers and β blockers in Marfan syndrome: An individual patient data meta-analysis of randomised trials. Lancet2022; 400: 822–831.
52.
MullenMJinXYChildA, et al. Irbesartan in Marfan syndrome (AIMS): A double-blind, placebo-controlled randomised trial. Lancet2019; 394: 2263–2270.
53.
MilleronOArnoultFRopersJ, et al. Marfan Sartan: A randomized, double-blind, placebo-controlled trial. Eur Heart J2015; 36: 2160–2166.
54.
FortezaAEvangelistaASánchezV, et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: A randomized clinical trial. Eur Heart J2016; 37: 978–985.
55.
Muiño-MosqueraLDe NobeleSDevosD, et al. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: A randomized, double-blind clinical trial. Acta Cardiol2017; 72: 616–624.
56.
ShoresJBergerKRMurphyEAPyeritzRE.Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med1994; 330: 1335–1341.
57.
SalimMAAlpertBSWardJCPyeritzRE.Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol1994; 74: 629–633.
58.
GroeninkMden HartogAWFrankenR, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: A randomized controlled trial. Eur Heart J2013; 34: 3491–3500.
59.
FrankenRden HartogAWRadonicT, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet2015; 8: 383–388.
60.
van AndelMMIndrakusumaRJalalzadehH, et al. Long-term clinical outcomes of losartan in patients with Marfan syndrome: Follow-up of the multicentre randomized controlled COMPARE trial. Eur Heart J2020; 41: 4181–4187.
61.
LacroRVDietzHCSleeperLA, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med2014; 371: 2061–2071.
62.
Teixido-TuraGFortezaARodríguez-PalomaresJ, et al. Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syndrome. J Am Coll Cardiol2018; 72: 1613–1618.
63.
YacoubMRadfordM.COMPARE and Pediatric Heart Network Investigator trials: Losartan finally validated in humans with Marfan, but much work remains!Glob Cardiol Sci Pract2014; 2014: 371–378.
64.
ElbadawiAOmerMAElgendyIY, et al. Losartan for preventing aortic root dilatation in patients with Marfan syndrome: A meta-analysis of randomized trials. Cardiol Ther2019; 8: 365–372.
65.
GaoLChenLFanL, et al. The effect of losartan on progressive aortic dilatation in patients with Marfan’s syndrome: A meta-analysis of prospective randomized clinical trials. Int J Cardiol2016; 217: 190–194.
66.
Al-AbchaASalehYMujerM, et al. Meta-analysis examining the usefulness of angiotensin receptor blockers for the prevention of aortic root dilation in patients with the Marfan syndrome. Am J Cardiol2020; 128: 101–106.
67.
BhattABBuckJSZuflachtJP, et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vasc Med2015; 20: 317–325.
68.
LiLYamaniNAl-NaimatS, et al. Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis. Eur J Prev Cardiol2020; 27: 1447–1450.
69.
KangYNChiSCWuMHChiuHH.The effects of losartan versus beta-blockers on cardiovascular protection in Marfan syndrome: A systematic review and meta-analysis. J Formos Med Assoc2020; 119(1 Pt 1): 182–190.
70.
JondeauGMilleronOEliahouL, et al. Marfan Treatment Trialists’ Collaboration in perspective: Sartans and beta-blockers in patients with Marfan syndrome. Arch Cardiovasc Dis2023; 116: 173–175.
71.
RobertsonDMTruongDTCoxDA, et al. Pediatric Heart Network Trial of losartan vs. atenolol in children and young adults with Marfan syndrome: Impact on prescription practices. Pediatr Cardiol2023; 44: 618–623.
72.
GranataASerranoFBernardWG, et al. An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death. Nat Genet2017; 49: 97–109.
SawadaHKatsumataYHigashiH, et al. Second heart field-derived cells contribute to angiotensin II-mediated ascending aortopathies. Circulation2022; 145: 987–1001.
76.
SicaDAGehrTWGhoshS.Clinical pharmacokinetics of losartan. Clin Pharmacokinet2005; 44: 797–814.
77.
ParkYASongYBYeeJ, et al. Influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite E-3174: A systematic review and meta-analysis. J Pers Med2021; 11: 617.
78.
FortuñoABidegainJRobadorPA, et al. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: Potential clinical implications in hypertension. Hypertension2009; 54: 744–750.
79.
OnettiYMeirellesTDantasAP, et al. NADPH oxidase 4 attenuates cerebral artery changes during the progression of Marfan syndrome. Am J Physiol Heart Circ Physiol2016; 310: H1081–1090.
80.
Jiménez-AltayóFMeirellesTCrosas-MolistE, et al. Redox stress in Marfan syndrome: Dissecting the role of the NADPH oxidase NOX4 in aortic aneurysm. Free Radic Biol Med2018; 118: 44–58.
81.
EmrichFPenovKArakawaM, et al. Anatomically specific reactive oxygen species production participates in Marfan syndrome aneurysm formation. J Cell Mol Med2019; 23: 7000–7009.
82.
Rodríguez-RoviraIArceCDe RyckeK, et al. Allopurinol blocks aortic aneurysm in a mouse model of Marfan syndrome via reducing aortic oxidative stress. Free Radic Biol Med2022; 193(Pt 2): 538–550.
83.
SaugeEPechkovskyDAtmuriNDP, et al. Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties. Vascul Pharmacol2022; 147: 107112.
84.
SaugeEWhiteZLizotteF, et al. Losartan and metabolite EXP3179 activate endothelial function without lowering blood pressure in AT2 receptor KO mice. Eur J Pharmacol2024; 977: 176663.
85.
SellersSLMiladNChanR, et al. Inhibition of Marfan syndrome aortic root dilation by losartan: Role of angiotensin II receptor type 1-independent activation of endothelial function. Am J Pathol2018; 188: 574–585.
86.
WatanabeTSuzukiJYamawakiH, et al. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: Angiotensin II type 1 receptor-independent effects of EXP3179. Circulation2005; 112: 1798–1805.
87.
TakagiHYamamotoHIwataK, et al. An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome. Int J Cardiol2012; 158: 101–102.
88.
CerasolaGNardiEMulèG, et al. Left ventricular mass in hypertensive patients with mild-to-moderate reduction of renal function. Nephrology (Carlton)2010; 15: 203–210.
89.
KakutaHSudohKSasamataMYamagishiS.Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res2005; 25: 41–46.
Hofmann BowmanMAEagleKAMilewiczDM.Update on clinical trials of losartan with and without β-blockers to block aneurysm growth in patients with Marfan syndrome: A review. JAMA Cardiol2019; 4: 702–707.
